• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology letters >Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy
【24h】

Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy

机译：表皮生长因子受体在局部晚期食管鳞癌中对放化疗患者的预后意义

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of the current study was to investigate the prognostic significance of epidermal growth factor receptor (EGFR) in patients with locally advanced esophageal squamous cell carcinoma (ESCC) receiving concurrent chemoradiotherapy (CCRT). In total, 47 patients with locally advanced ESCC who were treated with CCRT were included in the present study. The chemotherapeutics comprised of 5-fluorouracil (750-1,000 mg/m2/day; days one to five) and cisplatin (30 mg/m2/day; days one to three) in combination with radiation therapy (~60 Gy), which was performed as the initial treatment. EGFR expression was compared with the clinicopathological features, local recurrence, metastasis status and overall survival (OS). Overall, EGFR overexpression (percentage of immunoreactive tumor cells, ≥50%) was identified in 59.6% of the patients. The median survival time (MST) of the EGFR-positive group was 15 months and the MST of the EGFR-negative group was 23.5 months. A significant correlation was observed between EGFR overexpression and poor OS (P=0.024). EGFR overexpression was found to exhibit a correlation with lymph node metastasis (P=0.011), but no correlation was identified with other clinicopathological features. In addition, a correlation was identified between OS and gender (P=0.021), age (P=0.018), depth of invasion stage (P=0.035) and tumor location (P=0.023). EGFR overexpression determined by pretreatment biopsy may be a clinically useful biomarker for predicting the OS of ESCC patients.
机译：本研究的目的是研究表皮生长因子受体（EGFR）在接受同步放化疗（CCRT）的局部晚期食管鳞状细胞癌（ESCC）患者中的预后意义。本研究共纳入47例接受CCRT治疗的局部晚期ESCC患者。化学疗法由5-氟尿嘧啶（750-1,000 mg / m2 /天;第一至五天）和顺铂（30 mg / m2 /天;第一至三天）结合放疗（〜60 Gy）组成。作为初始治疗。将EGFR表达与临床病理特征，局部复发，转移状态和总生存期（OS）进行比较。总体而言，在59.6％的患者中发现了EGFR过表达（免疫反应性肿瘤细胞百分比，≥50％）。 EGFR阳性组的中位生存时间（MST）为15个月，EGFR阴性组的MST为23.5个月。 EGFR过表达与OS差之间存在显着相关性（P = 0.024）。发现EGFR过表达与淋巴结转移相关（P = 0.011），但与其他临床病理特征无相关性。另外，在OS和性别（P = 0.021），年龄（P = 0.018），浸润深度（P = 0.035）和肿瘤位置（P = 0.023）之间鉴定出相关性。通过预处理活检确定的EGFR过表达可能是预测ESCC患者OS的临床有用的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号